-
Achaogen's Phase 3 Shows 'Best Case Scenario'
Tuesday, December 13, 2016 - 4:19pm | 343Read More...Shares of Achaogen Inc (NASDAQ: AKAO) hit a new 52-week high of $16.07 after its lead product candidate plazomicin late-stage trial successfully achieved FDA primary endpoints in patients with complicated urinary tract infections (cUTI). The trial demonstrated non-inferiority compared to meropenem...
-
Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive
Monday, December 12, 2016 - 12:18pm | 360Read More...Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plunged more than 15 percent Monday morning and hit a new 52-week low of $109.80 after the company's board of directors announced CEO David Hallal will leave the company amid an ongoing audit and finance committee investigation. The company's...
-
A Primer On Endpoints: Global Blood Therapeutics
Tuesday, December 6, 2016 - 12:00pm | 345Read More...The 90 mg GBT440 data presented by Global Blood Therapeutics Inc (NASDAQ: GBT) at the American Society of Hematology meeting showed “consistent and durable responses”. Wedbush’s Heather Behanna reiterated an Outperform rating on the company, with a price target of $73. What The...
-
What To Expect From Catabasis Pharma's Proof Of Concept Study
Thursday, October 13, 2016 - 7:32am | 310Read More...Enrollment of MoveDMD proof-of-concept study of Catabasis Pharmaceuticals Inc’s (NASDAQ: CATB) NF-kB inhibitor, edasalonexent, has been completed. Data is expected in Q1 of 2017 and the risk/reward appears compelling, “with a best case scenario of a significant benefit (as measured by...
-
Wedbush Boosts Target On Sarepta Shares From $66 To $72 Amid US Launch Of Exondys 51
Monday, October 10, 2016 - 7:44am | 352Read More...Commenting on the U.S. commercial launch of Sarepta Therapeutics Inc’s (NASDAQ: SRPT) Exondys 51, Wedbush’s Heather Behanna said that the initial adoption would likely be rapid although logistical challenges may continue. The analyst maintained an Outperform rating on Sarepta, while...
-
DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta
Tuesday, October 4, 2016 - 11:00am | 295Read More...Sarepta Therapeutics Inc (NASDAQ: SRPT) forged a deal with Summit Therapeutics PLC (ADR) (NASDAQ: SMMT) to develop its utrophin pipeline in exchange for European rights and a Latin America option. Summit's stock soared higher by more than 100 percent following the announcement, but analysts...
-
The Search For Silver Linings In The Cloud Of Negative Novavax News
Monday, September 19, 2016 - 11:35am | 497Read More...It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. (NASDAQ: NVAX) shareholders are looking for any...
-
Wedbush Answers 'So, Now What?' For Novavax Shareholders
Friday, September 16, 2016 - 9:57am | 369Read More...On September 15, Novavax, Inc. (NASDAQ: NVAX) announced that its RSV vaccine had failed a pivotal trial in the elderly. Wedbush’s Heather Behanna downgraded the rating on the company from Outperform to Neutral, while lowering the price target from $14 to $2. Trial Failure Expressing surprise...
-
Need For New Drug Trial Increases Long-Term Risk For PTC Therapeutics, Says Wedbush
Tuesday, July 26, 2016 - 9:04am | 341Read More...PTC Therapeutics, Inc. (NASDAQ: PTCT) provided an update on July 25 regarding its discussions with European regulators and the path forward with the FDA, in association with Translarna. Wedbush’s Heather Behanna maintains a Neutral rating on the company, while lowering the price target from $...
-
Wedbush Bullish On Sarepta's Eteplirsen Data
Wednesday, July 20, 2016 - 8:42am | 214Read More...Wedbush’s Heather Behanna believes there is a “good chance” that eteplirsen would receive approval in 3Q16, if Sarepta Therapeutics Inc (NASDAQ: SRPT) is able to demonstrate “an eteplirsen-driven increase in dystrophin.” Behanna reiterated an Outperform rating on...
-
Achaogen Shares Upgraded To Outperform By Wedbush Following Optimistic Survey
Tuesday, June 14, 2016 - 9:06am | 167Read More...Wedbush's Heather Behanna upgraded Achaogen Inc (NASDAQ: AKAO) to Outperform, increasing the price objective from $7.00 to $10.00. After conducting a survey among physicians to analyze the gram-negative landscape and the "potential" for Achaogen's plazomicin, Behanna believes plazomicin had a "...
-
Wedbush Upgrades Sarepta To Outperform As 'FDA Comes Up With Option C'
Tuesday, June 7, 2016 - 8:57am | 281Read More...The FDA has requested Sarepta Therapeutics Inc (NASDAQ: SRPT) for dystrophin data in the ongoing evaluation of the eteplirsen New Drug Application [NDA]. Wedbush’s Heather Behanna upgraded the rating for the company from Neutral to Outperform, while raising the price target from $14 to $36...
-
Wedbush Initiates Coverage On Cubist Pharmaceuticals
Tuesday, November 4, 2014 - 12:09pm | 234Read More...Wedbush initiated coverage on Cubist Pharmaceuticals Inc (NASDAQ: CBST) with a Neutral rating and $70 price target. Analysts led by Heather Behanna commented that "Cubist is in transition from a one-product company to a leader in the antibiotic arena. Cubist has three antibiotic products...
-
UPDATE: Wedbush Initiates Coverage On Tetraphase Pharmaceuticals On Room To Grow
Tuesday, November 4, 2014 - 10:44am | 186Read More...In a report published Tuesday, Wedbush analyst Heather Behanna initiated coverage on Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) with an Outperform rating and $31.00 price target. In the report, Wedbush noted, “Tetraphase Pharmaceuticals is a Lexington, MA-based biotechnology company focused on...
-
UPDATE: Wedbush Initiates Coverage On Achaogen On High Clinical Risk
Tuesday, November 4, 2014 - 10:42am | 104Read More...In a report published Tuesday, Wedbush analyst Heather Behanna initiated coverage on Achaogen Inc (NASDAQ: AKAO) with a Neutral rating and $9.00 price target. In the report, Wedbush noted, “We are initiating coverage with a NEUTRAL rating and $9 price target. Our price target is achieved by...
